Effect of probiotics on the expression of Barrett’s oesophagus biomarkers

Journal of Medical Microbiology

Volumn 64, Issue 4, 2015, Pages 348-354

  Namin, Behrooz Mozaffari ^a,b   Daryani, Nasser Ebrahimi ^c   Mirshafiey, Abbas ^a   Yazdi, Mohammad Kazem Sharifi ^a   Dallal, Mohammad Mehdi Soltan ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLOOXYGENASE 2; INTERLEUKIN 18; MESSENGER RNA; PROBIOTIC AGENT; PROTEIN P53; TRANSCRIPTION FACTOR CDX1; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BARRETT ESOPHAGUS; BIFIDOBACTERIUM LONGUM; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LACTOBACILLUS ACIDOPHILUS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; BIFIDOBACTERIUM; GENE EXPRESSION PROFILING; GROWTH, DEVELOPMENT AND AGING; PATHOLOGY; THEORETICAL MODEL; TUMOR CELL LINE;

BARRETT ESOPHAGUS; BIFIDOBACTERIUM; BIOLOGICAL MARKERS; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; HUMANS; LACTOBACILLUS ACIDOPHILUS; MODELS, THEORETICAL; PROBIOTICS;

EID: 84927699837     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.000039     Document Type: Article

References (44)

1. Akatsu, H., Iwabuchi, N., Xiao, J. Z., Matsuyama, Z., Kurihara, R., Okuda, K., Yamamoto, T. & Maruyama, M. (2013). Clinical effects of probiotic B. longum BB536 on immune function and intestinal microbiota in elderly patients receiving enteral tube feeding. JPEN J Parenter Enteral Nutr 37, 631–640.
2. Allen, S. J., Wareham, K., Bradley, C., Harris, W., Dhar, A., Brown, H., Foden, A., Cheung, W. Y., Gravenor, M. B. & other authors (2012). A multicentre randomised controlled trial evaluating lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea in older people admitted to hospital: the PLACIDE study protocol. BMC Infect Dis 12, 108–116.
3. Babar, M., Ryan, A. W., Anderson, L. A., Segurado, R., Turner, G., Murray, L. J., Murphy, S. J., Johnston, B. T., Comber, H. & other authors (2012). Genes of the interleukin-18 pathway are associated with susceptibility to Barrett’s esophagus and esophageal adenocarcinoma. Am J Gastroenterol 107, 1331–1341.
4. Baldwin, C., Millette, M., Oth, D., Ruiz, M. T., Luquet, F. M. & Lacroix, M. (2010). Probiotic Lactobacillus acidophilus and L. casei mix sensitize colorectal tumoral cells to 5-fluorouracil-induced apoptosis. Nutr Cancer 62, 371–378.
5. Bermudez-Brito, M., Plaza-Díaz, J., Muñoz-Quezada, S., Gómez- Llorente, C. & Gil, A. (2012). Probiotic mechanisms of action. Ann Nutr Metab 61, 160–174.
6. Blackett, K. L., Siddhi, S. S., Cleary, S., Steed, H., Miller, M. H., Macfarlane, S., Macfarlane, G. T. & Dillon, J. F. (2013). Oesophageal bacterial biofilm changes in gastro-oesophageal reflux disease, Barrett’s and oesophageal carcinoma: association or causality? Aliment Pharmacol Ther 37, 1084–1092.
7. Fichter, C. D., Herz, C., Münch, C., Opitz, O. G., Werner, M. & Lassmann, S. (2011). Occurrence of multipolar mitoses and association with Aurora-A/-B kinases and p53 mutations in aneuploid esophageal carcinoma cells. BMC Cell Biol 12, 13.
8. Floch, M. H., Walker, W. A., Madsen, K., Sanders, M. E., Macfarlane, G. T., Flint, H. J., Dieleman, L. A., Ringel, Y., Guandalini, S. & other authors (2011). Recommendations for probiotic use-2011 update. J Clin Gastroenterol 45 (Suppl), S168–S171.
9. Furrie, E., Macfarlane, S., Kennedy, A., Cummings, J. H., Walsh, S. V., O’neil, D. A. & Macfarlane, G. T. (2005). Synbiotic therapy (B. longum/ Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 54, 242–249.
10. Girardin, M. & Seidman, E. G. (2011). Indications for the use of probiotics in gastrointestinal diseases. Dig Dis 29, 574–587.
11. Grover, S., Rashmi, H. M., Srivastava, A. K. & Batish, V. K. (2012). Probiotics for human health -new innovations and emerging trends. Gut Pathog 4, 15.
12. Haarman, M. & Knol, J. (2006). Quantitative real-time PCR analysis of fecal Lactobacillus species in infants receiving a prebiotic infant formula. Appl Environ Microbiol 72, 2359–2365.
13. Hashimoto, N. (2012). Expression of COX2 and p53 in rat esophageal cancer induced by reflux of duodenal contents. ISRN Gastroenterol 2012, 914824.
14. Hvid-Jensen, F., Pedersen, L., Drewes, A. M., Sørensen, H. T. & Funch-Jensen, P. (2011). Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med 365, 1375–1383.
15. Khailova, L., Mount Patrick, S. K., Arganbright, K. M., Halpern, M. D., Kinouchi, T. & Dvorak, B. (2010). B. bifidum reduces apoptosis in the intestinal epithelium in necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol 299, G1118–G1127.
16. Khan, M. W., Zadeh, M., Bere, P., Gounaris, E., Owen, J., Klaenhammer, T. & Mohamadzadeh, M. (2012). Modulating intestinal immune responses by lipoteichoic acid-deficient Lactobacillus acidophilus. Immunotherapy 4, 151–161.
17. Kim, Y., Lee, D., Kim, D., Cho, J., Yang, J., Chung, M., Kim, K. & Ha, N. (2008). Inhibition of proliferation in colon cancer cell lines and harmful enzyme activity of colon bacteria by B. adolescentis SPM0212. Arch Pharm Res 31, 468–473.
18. Kun, C., Liang, N., Luo, X. & Zhang, T. C. (2013). Lactobacillus acidophilus strain suppresses the transcription of proinflammatoryrelated factors in human HT-29 cells. JMicrobiol Biotechnol 23(1), 64–68.
19. Kwon, H.-S., Yang, E. H., Lee, S.-H., Yeon, S.-W., Kang, B.-H. & Kim, T.-Y. (2005). Rapid identification of potentially probiotic B. species by multiplex PCR using species-specific primers based on the region extending from 16S rRNA through 23S rRNA. FEMS Microbiol Lett 250, 55–62.
20. Lee, N. K., Park, J. S., Park, E. & Paik, H. D. (2007). Adherence and anticarcinogenic effects of Bacillus polyfermenticus SCD in the large intestine. Lett Appl Microbiol 44, 274–278.
21. Lim, Y. C. & Fitzgerald, R. C. (2013). Diagnosis and treatment of Barrett’s oesophagus. Br Med Bull 107, 117–132.
22. Macfarlane, G. T. & Cummings, J. H. (2002). Probiotics, infection and immunity. Curr Opin Infect Dis 15, 501–506.
23. Macfarlane, G. T., Steed, H. & Macfarlane, S. (2008). Bacterial metabolism and health-related effects of galacto-oligosaccharides and other prebiotics. J Appl Microbiol 104, 305–344.
24. Madsen, K. L. (2012). Enhancement of epithelial barrier function by probiotics. J Epithel Biol Pharmacol 5, 55–59.
25. Makita, K., Kitazawa, R., Semba, S., Fujiishi, K., Nakagawa, M., Haraguchi, R. & Kitazawa, S. (2013). Cdx2 expression and its promoter methylation during metaplasia-dysplasia-carcinoma sequence in Barrett’s esophagus. World J Gastroenterol 19, 536–541.
26. Malaguarnera, G., Leggio, F., Vacante, M., Motta, M., Giordano, M., Bondi, A., Basile, F., Mastrojeni, S., Mistretta, A. & other authors (2012). Probiotics in the gastrointestinal diseases of the elderly. J Nutr Health Aging 16, 402–410.
27. Mozaffari namin, B., Soltan Dallal, M. M. & Daryani, N. E. (2015). The effect of Campylobacter concisus on the expression of IL18, TNFa, and p53 on Barrett’s oesophagus. J J Microbiol (in press).
28. Ng, S. C., Hart, A. L., Kamm, M. A., Stagg, A. J. & Knight, S. C. (2009). Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis 15, 300–310.
29. Nguyen, G. H., Schetter, A. J., Chou, D. B., Bowman, E. D., Zhao, R., Hawkes, J. E., Mathé, E. A., Kumamoto, K., Zhao, Y. & other authors (2010). Inflammatory and microRNA gene expression as prognostic classifier of Barrett’s-associated esophageal adenocarcinoma. Clin Cancer Res 16, 5824–5834.
30. Otte, J.-M., Mahjurian-Namari, R., Brand, S., Werner, I., Schmidt, W. E. & Schmitz, F. (2009). Probiotics regulate the expression of COX-2 in intestinal epithelial cells. Nutr Cancer 61, 103–113.
31. Quigley, E. M. M. (2012). Prebiotics and probiotics: their role in the management of gastrointestinal disorders in adults. Nutr Clin Pract 27, 195–200.
32. Rijkers, G. T., de Vos, W. M., Brummer, R. J., Morelli, L., Corthier, G. & Marteau, P. (2011). Health benefits and health claims of probiotics: bridging science and marketing. Br J Nutr 106, 1291–1296.
33. Russo, A., Bronte, G., Cabibi, D., Bazan, V., Cicero, G., Bertani, A., Rizzo, S. & Fiorentino, E. (2013). The molecular changes driving the carcinogenesis in Barrett’s esophagus: Which came first, the chicken or the egg? Crit Rev Oncol Hematol 86, 278–289.
34. Sharma, P., Hawes, R. H., Bansal, A., Gupta, N., Curvers, W., Rastogi, A., Singh, M., Hall, M., Mathur, S. C. & other authors (2013). Standard endoscopy with random biopsies versus narrow band imaging targeted biopsies in Barrett’s oesophagus: a prospective, international, randomised controlled trial. Gut 62, 15–21.
35. Smith, A. R., Macfarlane, G. T., Reynolds, N., O’May, G. A., Bahrami, B. & Macfarlane, S. (2012). Effect of a synbiotic on microbial community structure in a continuous culture model of the gastric microbiota in enteral nutrition patients. FEMS Microbiol Ecol 80, 135–145.
36. Soltan Dallal, M. M., Yazdi, M. H., Holakuyee, M., Hassan, Z. M., Abolhassani, M. & Mahdavi, M. (2012). Lactobacillus casei ssp.casei induced Th1 cytokine profile and natural killer cells activity in invasive ductal carcinoma bearing mice. Iran J Allergy Asthma Immunol 11, 183–189.
37. Steed, H., Macfarlane, G. T., Blackett, K. L., Bahrami, B., Reynolds, N., Walsh, S. V., Cummings, J. H. & Macfarlane, S. (2010). Clinical trial: the microbiological and immunological effects of symbiotic consumption - a randomized double-blind placebo-controlled study in active Crohn’s disease. Aliment Pharmacol Ther 32, 872–883.
38. Thrift, A. P., Garcia, J. M. & El-Serag, H. B. (2014). A multibiomarker risk score helps predict risk for Barrett’s esophagus. Clin Gastroenterol Hepatol 12, 1267–1271.
39. Weng, M. & Walker, W. A. (2013). The role of gut microbiota in programming the immune phenotype. J Dev Orig Health Dis 4, 203–214.
40. Werner, M. & Laßmann, S. (2012). [Update on Barrett esophagus and Barrett carcinoma]. Pathologe 33 (Suppl. 2), 253–257 (in German).
41. Yazdi, M. H., Soltan Dallal, M. M., Hassan, Z. M., Holakuyee, M., Agha Amiri, S., Abolhassani, M. & Mahdavi, M. (2010). Oral administration of Lactobacillus acidophilus induces IL-12 production in spleen cell culture of BALB/c mice bearing transplanted breast tumour. Br J Nutr 104, 227–232.
42. Zanello, G., Berri, M., Dupont, J., Sizaret, P.-Y., D’Inca, R., Salmon, H. & Meurens, F. (2011). Saccharomyces cerevisiae modulates immune gene expressions and inhibits ETEC-mediated ERK1/2 and p38 signaling pathways in intestinal epithelial cells. PLoS ONE 6, e18573.
43. Zhu, Y., Michelle Luo, T., Jobin, C. & Young, H. A. (2011). Gutmicrobiota and probiotics in colon tumorigenesis. Cancer Lett 309, 119–127.
44. Zimmerman, T. G. (2014). Common questions about Barrett esophagus. Am Fam Physician 89, 92–98.